Navigation Links
Biomarkers for Alzheimer's disease can be trusted in clinical trials

Gteborg, Sweden, 15 November 2007 -- The best-established biomarkers for Alzheimers disease have a low natural variation over two years. The results speak for the inclusion of these biomarkers in clinical trials of novel drugs against Alzheimers disease.

The results are presented by researchers at the Sahlgrenska Academy at Gteborg University, Sweden, in the November 2007 issue of the Journal of Alzheimers Disease.

We show that the best-established diagnostic biomarkers for Alzheimers disease stay at basically the same level during two years in patients with early Alzheimers disease. This means that the biomarkers could be useful for detecting even minor biochemical changes induced by treatment in the clinical trials of novel drugs against Alzheimers, says Henrik Zetterberg, Associate Professor at the Sahlgrenska Academy.

Dr Zetterberg and colleagues analyzed cerebrospinal fluid from more than 80 patients with mild cognitive impairment. Some of these patients developed full-blown Alzheimers disease. The measured levels of the tau and amyloid- proteins were compared in samples drawn from the same patients two years apart.

If a novel drug candidate actually stops or slows down the neurodegenerative disease process in Alzheimer's disease, we should expect a normalized tau concentration in cerebrospinal fluid in patients on active treatment. Such a change should be readily detectable also in a small and inexpensive pilot study, given the low intra-individual variation in biomarker levels over time that was detected in our study, Dr Zetterberg says.

Alzheimer's disease is an age-related brain-damaging disorder that results in progressive cognitive impairment and death. Three decades of progress have resulted in a profound understanding of the molecular mechanisms underlying the disease. In the past 10 years, this knowledge has translated into a range of targets for therapy, the most promising of which is amyloid-.


Contact: Associate Professor Henrik Zetterberg
IOS Press

Related medicine news :

1. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
2. Study makes progress in zoning in on biomarkers for better colon cancer treatment
3. Biomarkers predict risk for invasive breast cancer years before the tumor develops
4. JDRF and Lilly partner to fund research to identify beta cell biomarkers
5. Smoking may strongly increase long-term risk of eye disease
6. Pot bellies linked to early signs of cardiovascular disease
7. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
8. Radiologists encouraged to look beyond cancer for clinically unseen diseases
9. Use of certain lipid measures not more effective in predicting coronary heart disease
10. Role seen for cannabis in helping to alleviate allergic skin disease
11. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
Post Your Comments:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: